Patent claims were brought by EEMSO over the Companion80 product, an inflammatory treatment manufactured by Iomed which uses iontophoresis technology.
“It was essential that we aggressively defend against these meritless claims to preserve the integrity and value of our proprietary iontophoresis technology and products, including our Companion80 product,” said Robert Lollini, president and CEO.
Currently more advanced computer controlled iontophoresis systems, such as Iomed’s Phoresor System, remain the preferred products among medical professionals. However, a niche market has developed for integrated single-use, disposable iontophoretic drug delivery patches, such as the Companion80 product.